PL3319635T3 - Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej - Google Patents

Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej

Info

Publication number
PL3319635T3
PL3319635T3 PL16734013T PL16734013T PL3319635T3 PL 3319635 T3 PL3319635 T3 PL 3319635T3 PL 16734013 T PL16734013 T PL 16734013T PL 16734013 T PL16734013 T PL 16734013T PL 3319635 T3 PL3319635 T3 PL 3319635T3
Authority
PL
Poland
Prior art keywords
cancer therapy
whole cell
checkpoint inhibitor
cell mycobacterium
mycobacterium
Prior art date
Application number
PL16734013T
Other languages
English (en)
Inventor
Charles AKLE
Laura Rosa Brunet
Original Assignee
Immodulon Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511121.4A external-priority patent/GB201511121D0/en
Priority claimed from GBGB1511120.6A external-priority patent/GB201511120D0/en
Application filed by Immodulon Therapeutics Limited filed Critical Immodulon Therapeutics Limited
Publication of PL3319635T3 publication Critical patent/PL3319635T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
PL16734013T 2015-06-24 2016-06-24 Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej PL3319635T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1511121.4A GB201511121D0 (en) 2015-06-24 2015-06-24 Cancer therapy
GBGB1511120.6A GB201511120D0 (en) 2015-06-24 2015-06-24 Cancer therapy
PCT/GB2016/051893 WO2016207646A1 (en) 2015-06-24 2016-06-24 A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
EP16734013.2A EP3319635B1 (en) 2015-06-24 2016-06-24 A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy

Publications (1)

Publication Number Publication Date
PL3319635T3 true PL3319635T3 (pl) 2021-10-25

Family

ID=56296853

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16734013T PL3319635T3 (pl) 2015-06-24 2016-06-24 Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej

Country Status (15)

Country Link
US (2) US11207405B2 (pl)
EP (2) EP3868406A1 (pl)
JP (3) JP6892443B2 (pl)
KR (1) KR20180015269A (pl)
CN (2) CN114344462A (pl)
AU (1) AU2016281765B2 (pl)
BR (1) BR112017028163A2 (pl)
CA (1) CA2990107A1 (pl)
ES (1) ES2879248T3 (pl)
IL (1) IL256467B (pl)
MX (1) MX2017016931A (pl)
PL (1) PL3319635T3 (pl)
PT (1) PT3319635T (pl)
RU (1) RU2733033C2 (pl)
WO (1) WO2016207646A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US20190312297A1 (en) * 2016-12-19 2019-10-10 Showa Denko K.K. Method for operating redox flow battery
CN110720039A (zh) * 2017-05-30 2020-01-21 百时美施贵宝公司 Lag-3阳性肿瘤的治疗
EP3421607A1 (en) * 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
US20210239955A1 (en) * 2018-06-08 2021-08-05 The Board Of Trustees Of The Leland Stanford Junior University Near infra-red light sheet microscopy through scattering tissues
GB201810058D0 (en) * 2018-06-19 2018-08-08 Cytovation As Combination therapy using a peptide
JP2021529741A (ja) * 2018-06-25 2021-11-04 イモデュロン セラピューティクス リミテッド がん治療
GB201919428D0 (en) * 2019-12-30 2020-02-12 Immodulon Therapeutics Ltd Immunotherapeutic treatment of cancer
WO2022096896A1 (en) * 2020-11-06 2022-05-12 Immodulon Therapeutics Limited Mycobacterial immunotherapy for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
CA2095855C (en) 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
CN1129453C (zh) * 1996-12-18 2003-12-03 斯坦福鲁克有限公司 用于下调免疫系统Th2活性的母牛分枝杆菌
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
WO2000064476A2 (en) 1999-04-23 2000-11-02 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
WO2003049751A1 (en) 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
JP4409430B2 (ja) * 2002-07-03 2010-02-03 小野薬品工業株式会社 免疫賦活組成物
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US7799776B2 (en) 2004-07-13 2010-09-21 The University Of British Columbia Indoleamine 2,3-dioxygenase (IDO) inhibitors
EP1863532A1 (en) 2005-03-23 2007-12-12 Pfizer Products Incorporated Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
WO2007050405A2 (en) 2005-10-21 2007-05-03 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
WO2007112316A2 (en) 2006-03-24 2007-10-04 Morton Donald L Mycobacterial immunotherapy for cancer treatment
US8109993B2 (en) 2006-05-25 2012-02-07 Deep Vein Medical, Inc. Device for regulating blood flow
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
PT2172211E (pt) 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
JP5310222B2 (ja) 2009-04-20 2013-10-09 富士通株式会社 電荷分配型デジタル・アナログ変換器及びそれを有する逐次比較型アナログ・デジタル変換器
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CA2829217C (en) 2011-03-09 2019-04-09 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
MX341076B (es) 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
CN103796680A (zh) 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
WO2013114367A2 (en) * 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) * 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
KR20160066554A (ko) * 2013-10-25 2016-06-10 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
EP3092004A4 (en) * 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
KR101724963B1 (ko) 2015-12-09 2017-04-10 현대자동차주식회사 전자식 다기능 스위치의 턴신호 제어장치 및 그 제어방법
JP2021529741A (ja) 2018-06-25 2021-11-04 イモデュロン セラピューティクス リミテッド がん治療

Also Published As

Publication number Publication date
PT3319635T (pt) 2021-07-07
WO2016207646A1 (en) 2016-12-29
EP3319635A1 (en) 2018-05-16
AU2016281765B2 (en) 2022-06-16
JP6892443B2 (ja) 2021-06-23
JP7393384B2 (ja) 2023-12-06
BR112017028163A2 (pt) 2018-08-28
RU2018102547A3 (pl) 2019-12-24
JP2023118968A (ja) 2023-08-25
US11207405B2 (en) 2021-12-28
KR20180015269A (ko) 2018-02-12
ES2879248T3 (es) 2021-11-22
IL256467B (en) 2021-12-01
IL256467A (en) 2018-02-28
CN107847598B (zh) 2022-01-25
AU2016281765A1 (en) 2018-01-18
JP2018518539A (ja) 2018-07-12
CA2990107A1 (en) 2016-12-29
JP2021120418A (ja) 2021-08-19
RU2018102547A (ru) 2019-07-24
RU2733033C2 (ru) 2020-09-28
EP3868406A1 (en) 2021-08-25
US20180185479A1 (en) 2018-07-05
US20220111046A1 (en) 2022-04-14
CN107847598A (zh) 2018-03-27
EP3319635B1 (en) 2021-04-21
CN114344462A (zh) 2022-04-15
MX2017016931A (es) 2018-09-26

Similar Documents

Publication Publication Date Title
IL246083A0 (en) A barrier inhibitor and a whole mycobacterium cell, for use in cancer treatment
IL256467A (en) Block an entire cell control and microbacterium for cancer treatment
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
HK1254976A1 (zh) 造血幹細胞和抗癌免疫檢查點抑制劑的組合療法
HK1257206A1 (zh) 用於對便携式收聽設備進行充電和固定的盒
IL266362A (en) Immunologically differentiated cells for use in cellular therapy
HUE043847T2 (hu) Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
IL265274A (en) Combined treatment of antibody and checkpoint inhibitor
IL251630A0 (en) Combined therapy for use in cancer treatment
PL3371165T3 (pl) Inhibitor btk do zastosowania w terapii rakowej
HK1209799A1 (en) A non-invasion cancer detection method and a kit for performing the same
GB201510758D0 (en) Novel TNFa structure for use in therapy
HK1249852A1 (zh) 與癌症藥物的聯合治療中的nk-92細胞
GB201511382D0 (en) Novel compounds and their use in therapy
IL262656A (en) Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
GB201510292D0 (en) Improvements in Dosimetry Techniques for Radiotherapy
GB201510288D0 (en) Improvements in dosimetry techniques for radiotherapy
SI3463436T1 (sl) Cepivo v kombinaciji z zaviralcem imunske kontrolne točke za uporabo pri zdravljenju raka
GB201702160D0 (en) Inhibitors for use in therapy
GB2526889B (en) Battery case and electrode plate set for use in the same
GB201511158D0 (en) Cell modification and application in therapy
GB201409978D0 (en) Novel compounds and their use in therapy